News articles about Albireo Pharma (NASDAQ:ALBO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Albireo Pharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.761731606839 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Albireo Pharma (NASDAQ ALBO) traded down $0.67 on Friday, reaching $29.46. The company’s stock had a trading volume of 19,659 shares, compared to its average volume of 51,205. The company has a market capitalization of $268.14, a P/E ratio of 13.58 and a beta of 1.43. Albireo Pharma has a twelve month low of $15.31 and a twelve month high of $30.80.

A number of brokerages recently commented on ALBO. Needham & Company LLC reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Thursday, October 26th. ValuEngine downgraded Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Wedbush reiterated a “buy” rating on shares of Albireo Pharma in a report on Wednesday, January 3rd. Zacks Investment Research downgraded Albireo Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Finally, Cowen reiterated a “buy” rating on shares of Albireo Pharma in a report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Albireo Pharma currently has a consensus rating of “Buy” and a consensus target price of $54.50.

In other Albireo Pharma news, major shareholder Plc Astrazeneca sold 500,000 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-albireo-pharma-albo-stock-price/1805867.html.

Albireo Pharma Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Insider Buying and Selling by Quarter for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.